Proteomic Analysis in Multiple Myeloma Research

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	ČUMOVÁ Jana POTÁČOVÁ Anna ZDRÁHAL Zbyněk HÁJEK Roman
Year of publication	2011
Type	Article in Periodical
Magazine / Source	Molecular biotechnology
MU Faculty or unit	Faculty of Medicine
Citation
Doi	http://dx.doi.org/10.1007/s12033-010-9326-x
Field	Oncology and hematology
Keywords	proteomics; multiple myeloma; mass spectrometry; biomarker
Description	Multiple myeloma (MM) is an incurable plasma cell (PC) malignancy characterized by the accumulation of monoclonal PCs in the bone marrow. For deeper understanding of the molecular mechanisms involved in the development of this disease, the influence of microenvironment, or the prediction of response of tumor PCs to anti-MM treatment, it is possible to use modern technologies for genomic and proteomic analyses. Due to progress in instrumentation, one of the main tools of proteomic analysis is mass spectrometry in combination with chosen separation techniques. This review will provide a short survey of the most commonly used proteomic techniques and show examples of their applications in MM proteome studies.
Related projects:	Molecular basis of cell and tissue regulations University Research Centre - Czech Myeloma Group From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies